Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47.9M
-
Number of holders
-
253
-
Total 13F shares, excl. options
-
50.7M
-
Shares change
-
+819K
-
Total reported value, excl. options
-
$3.38B
-
Value change
-
-$105M
-
Put/Call ratio
-
1
-
Number of buys
-
146
-
Number of sells
-
-158
-
Price
-
$66.64
Significant Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q2 2021
351 filings reported holding HAE - HAEMONETICS CORP - Common Stock as of Q2 2021.
HAEMONETICS CORP - Common Stock (HAE) has 253 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 50.7M shares
.
Largest 10 shareholders include BlackRock Inc. (5.98M shares), VANGUARD GROUP INC (4.89M shares), Neuberger Berman Group LLC (3.76M shares), WELLINGTON MANAGEMENT GROUP LLP (3.69M shares), Capital Research Global Investors (2.68M shares), STATE STREET CORP (1.67M shares), FRANKLIN RESOURCES INC (1.34M shares), Fisher Asset Management, LLC (1.1M shares), LONDON CO OF VIRGINIA (1.05M shares), and LGT CAPITAL PARTNERS LTD. (953K shares).
This table shows the top 253 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.